NEW YORK (GenomeWeb) – Horizon Discovery today announced an agreement with Swift Biosciences to incorporate Horizon's human genomic reference standards into Swift's Accel-Amplicon 56G Oncology Panel.

Swift will include Horizon's HDx Quantitative Multiplex Reference Standard material as a positive control in its single-tube, 56-gene panel. The assay covers genes clinically relevant to cancer and generates sequencing libraries for use on common next-generation sequencing platforms from both formalin-fixed, paraffin-embedded and circulating, cell-free DNA samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.